ALS/MND International Alliance Scientific Advisory Council

MOFF attended the ALS/MND International Alliance Scientific Advisory Council Meeting on June 17th (at 4 AM PST). It was worth it. The event was hosted by The ALS Association and featured neurologists from 10 different countries.

Who attended this International Advisory Council Meeting?

Dr. Jeanine Heckmann (South Africa)

Dr. David Taylor (Canada) – facilitator

Dr. Kuldip Dave (USA)

Dr. Nicolas Cole (UK)

Dr. Caroline Ingre (Sweden)

Dr. Gethin Thomas (Australia)

Dr. Piera Pasenelli (USA)

Absent: Dr. Qing Liu (China), Dr. Adriano Chio (Italy) and Dr. Luis Barbeito (Uruguay)

What did they discuss?

The main discussion topic was prompted by the facilitator, David Taylor. He began the meeting by encouraging participants to share what they are most excited about in the ALS/MND field. Responses varied, but there was a general consensus around 3 topics:

1. Platform trial design

The Tricals Platform Trial (UK) and the Healey Platform Trial (USA) design are both incredible tools to test new therapies for ALS. They are not only cost-effective, but time-efficient and patient-centric as well. The platform concept was originally implemented in oncology, and in 2019 was adapted to the ALS field. Historically, trials have required a 50/50 placebo control. In cancer and ALS, the fatality rate of these diseases make it almost unethical to put a patient in a placebo control group. The platform trial takes this into consideration; only 1/3 of patients will receive a placebo and for a shorter duration (6 months). The platform trial design allows for more therapy options to be tested at once: 5 for the Healey Trial and 2 for the Tricals Trial. The treatments being tested in the Tricals Trial are Lithium Carbonate and Triumeq. Read the MOFF article on the Healey Trial to learn what treatments are being used in the U.S. trial.

Dr. Pasenelli and Dr. Cole had a productive dialogue about comparing trial outcome measures. This discussion occurred after Dr. Cole claimed the Tricals Trial had more outcome measures than the Healey Trial. While this is likely because the FDA bases it’s outcome measures on the ALSFRS-R score and the EMA bases their outcome measure reporting on survival, a more thorough comparison is warranted.

2. Gene therapies

Gene therapies are the future! It is not an unrealistic claim to say that specific genetic forms of ALS will be curable within the next 2-5 years. Researchers are targeting ALS cases with the SOD1, FUS, and C9orF72 genetic mutations. Two examples of such therapies are Tofersen (Biogen) and AVSX-301 (Avexis/Novartis). Phase 3 trials of Tofersen are currently being conducted in the U.S. and multiple other countries including Japan, Canada, and Italy. The aims of these gene therapies are to replace genes, silence genes, or deliver proteins that boost motor neuron function. Currently, the two most promising ways to deliver these therapeutic benefits is via Adeno-associated viruses (AAVs) or Antisense Oligonucleotide (ASOs).

These gene therapies are the first to modify ALS disease progression. This is amazing given the fact the three current FDA approved medications for ALS simply claim to extend patients’ lives by 3 or 6 months. What is even more incredible about the development of gene therapies for ALS, specifically, Tofersen, is that Dr. Alan Smith wrote about this therapy in his book: Handbook of Amyotrophic Lateral Sclerosis. It was published in 1992. Patients are finally gaining access to treatments that have been conceptualized almost 30 years ago.

Keep in mind that these genetic therapies will only be effective for 10% of the ALS population. That being said, C9orf72 has implications in the sporadic form of ALS as well so whatever pathogenetic insights they extract from these ongoing clinical trials, will inform future studies done for sporadic ALS.

3. Biomarker usage

We can finally objectively measure if drugs are slowing ALS disease progression! “Biomarker” has been a buzz word in the ALS community for years. A biomarker, loosely defined, is a biological sample that can be used to screen, diagnose or monitor disease progression. The majority of  excitement during the meeting was centered on the use of pharmacodynamic biomarkers, in upcoming clinical trials. Below is an image of the many potential measurements of ALS disease progression that newer trials, specifically the Healey Platform Trial, will incorporate.

(Image adapted from a 2019 Mass General presentation on the Healey Platform Trial. The presentation was led by Dr. Sabrina Paganoni and Dr. Ben Saville)

For the sake of time and space, this post will not going into the details of each measurement. More information can be found in this Frontiers article. The second takeaway from council’s the biomarker discussion was one of hope. Dr. Pasenelli described an important perspective shift that has occurred in the ALS research community. To paraphrase, she recognized that 7-10 years ago, researchers joined the ALS therapeutic area for the general, rather unexciting discipline of researching. Now, each ALS research investigations could lead to a potential therapeutic target or a biomarker discovery. The hope of actually discovering something is alive and is encouraging more individuals to join the field. This was incredibly encouraging to hear.

Sidenote:

South Africa:  South Africa gets their own blurb because during the meeting it sounded like Dr. Jeannine Heckmann was on a literal ALS battlefront. She began the meeting by stating there are only 3 interdisciplinary clinics in South Africa and the some of the medical professionals attend the clinics once a month. Dr. Heckmann went on to share a very moving story about recent ALS diagnosis she had to give while the patient was already in need of a ventilator and there were limited ventilator resources. Their country has limited resources to Rilutek, which is 10-15 years behind USA standards. In conclusion, Dr. Heckmann is a saint and needs back up. Also, the South African ALS patient community needs support ASAP.

Thank you to all the ALS/MND Internationals Alliance Scientific Council Members! We greatly appreciate all of your contributions to the ALS field. 

Neil Clayton
Development Coordinator
MOFF is pleased to welcome Neil Clayton to the MOFF team as Development Coordinator and Strategic Thought Partner. Neil joins MOFF after working in law enforcement in San Luis Obispo County for over 20 years. During his law enforcement career, Neil volunteered with law enforcement-related non profits at both the local and state level. Neil recently retired from the SLO County District Attorney’s Office.

Neil supports MOFF’s mission and shares our organizational values having experienced the loss of a loved one to ALS in 2015. Driven by his experience with the challenges of caring for a loved one battling this disease locally, Neil is determined to help families living on the Central Coast find and maintain the medical care they need as well as do everything possible to support finding a cure.

In his spare time, Neil enjoys hiking, fishing and traveling with his wife Jennifer and their two children.

Gabriella Lyon
Social Media Coordinator
Gabriella is the Coordinator for Administrative Support at Associated Students, Inc. at Cal Poly San Luis Obispo. In her spare time, she serves as the Social Media Coordinator for MOFF. With a background in advocacy work and a personal understanding of the impact ALS has on families, Gabriella is committed to supporting and uplifting the ALS community. She holds a Bachelor of Arts degree in Communication and Sociology from the University of California, Davis.

Natalie Fernandez
Program Director, COO/CFO
Natalie is a Senior Consultant at Beghou Consulting. In her spare time she serves as Fractional COO/ CFO at MOFF. She is part of the Community Research Committee at the ALS Network and is a member of the Patient and Caregiver Advisory Committee at the ALS Association. Natalie holds an MBA degree in Pharmaceutical and Healthcare Business from the Philadelphia College of Pharmacy and an undergraduate degree from NYU. Natalie is motivated to find a cure for ALS to prevent individuals from experiencing what her mother, Martha, went through in her ALS journey. Natalie joined the ALS community when the saying was “ALS is not an incurable disease, it was just an underfunded one.” Today, it is now well funded. Let’s go! #findacureforALS

Andrea O'Brien
Board Member, Co-Founder, Secretary
Andrea O'Brien is a former HR professional who brings a wealth of experience in people and business to her role as Board Member, Co-Founder and Secretary at the Martha Olson-Fernandez Foundation. She holds a bachelor's degree from California Polytechnic State University and after building her professional career, she chose to dedicate her time to raising her son and daughter, embracing the opportunity to be present for their early years and family life. Her commitment to the Foundation is deeply personal, inspired by its namesake, her mother, Martha. Through her service, she honor's Martha's strength and resilience while advancing awareness, support and resources for individuals and families affected by ALS. She is proud to combine her professional experience and personal passion in support of the Foundation's mission.

John Ronca
Board Member
John joined the MOFF board of directors in April 2020. Bio coming soon.

Cheri Humphrey
Board Member
Cheri Humphrey joined the MOFF board of directors in August of 2019. Cheri grew up in Dixon, CA and moved to San Luis Obispo to attend Cal Poly. It was there that she met her husband Jim. They now reside in SLO and have a daughter, Victoria and a son, Riley. Cheri is instrumental in the operations of the iconic Madonna Inn, which she has been the Retail Manager of since 1989. Cheri and her family have been ALS advocates since the inception of MOFF. We are honored to have Cheri as part of the board to guide community outreach and continue raising awareness of ALS prevalence on the Central Coast.

Ian Parkinson
Board Member
We are very excited to welcome San Luis Obispo County Sheriff, Ian Parkinson, into his second two-year term as a member of the Martha Olson-Fernandez Foundation Board. Ian has served as Sheriff since 2011 and is well known in the community for this tireless efforts to improve the law enforcement processes of SLO County. Ian knew Martha Olson-Fernandez and has been a supporter of MOFF since 2012. We are very grateful for his commitment to help us carry out our mission to fight ALS through patient care and research. We look forward to utilizing his strategic insights and community outreach to further the MOFF mission.

Larry Fernandez
Director, CEO
Larry is a consultant in the vegetable seed industry. He has been an entrepreneur in the vegetable seed industry for 40 plus years. Larry is very proud of his daughter’s scholastic achievements, working careers and their growing families. He enjoys being a grandpa 3 times over, hunting and fishing when time permits. His goal in life is to honor his wife (Martha Olson-Fernandez) wishes of Finding a cure for ALS and assisting those living with ALS today so they never have to go through the processes she did while living with ALS.